Topical compositions for the treatment of alopecia areata
A cyclosporine-based topical composition in semifluorinated alkane addresses the need for effective alopecia areata treatment with reduced side effects, offering a targeted and compliant solution for hair loss and growth.
WO2026104414A1 Publication Date: 2026-05-21DERMALIQ THERAPEUTICS GMBH +1
6 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/082663
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-12
- Filing Date
- 2025-11-11
- Publication Date
- 2026-05-21
AI Technical Summary
Technical Problem
Current treatments for alopecia areata, such as corticosteroids and oral cyclosporine, are associated with side effects and there is a need for an effective topical treatment without systemic side effects.
Method used
A liquid pharmaceutical composition comprising cyclosporine dissolved in a semifluorinated alkane, optionally with a co-solvent, for topical application to treat alopecia areata and stimulate hair growth.
Benefits of technology
Provides an effective and targeted topical treatment for alopecia areata with reduced side effects, allowing for localized application and improved patient compliance.
✦ Generated by Eureka AI based on patent content.
Abstract
The disclosure relates to a pharmaceutical composition comprising cyclosporine dissolved in a semifluorinated alkane and optionally a co-solvent, for use in the topical treatment of alopecia areata.
Need to check novelty before this filing date? Find Prior Art